ZACKS RESEARCH

FUNDS

PORTFOLIO

BROKER RESEARCH

MARKETS

SCREENING

EDUCATION

SERVICES

Earnings

EPS Surprises

Mutual Funds

Options

My Account

Help

What's Up With These Ridiculous Stock Gains?

Steve Reitmeister didn't want me to tell you this. He felt that one strategy's performance stands out so much that... Read on >>

Quote:

Search for Ticker

Free Membership

Search:

SLXP: Salix Pharmaceuticals Ltd - Full Company Report Enter Ticker:

Quote	Estimates	Charts	Company Reports	News	Financials

Full Company Report \| Estimates \| Brokerage Recommendations \| Comparison to Industry \| Insiders \| Brokerage Reports \| Zacks Equity Research \| Annual Report

SALIX PHARMACEUTICALS LTD (NASD)
SLXP	23.68	0.12	(0.51%)	Vol. 55,860	10:29 ET

Salix Pharmaceuticals, Ltd. objective is to be a market-driven specialtypharmaceutical company focussed on the needs of physicians specializing ingastroenterology. The company intends to establish a small direct sales force to promote its products to this specialist audience. The company's strategy is to identify and acquire products that have near-term commercial potential and apply its regulatory and product development expertise to commercialize these products. The company selects products that it believes serve a gastrointestinal disease.

General Information

SALIX PHARM-LTD

1700 Perimeter Park Drive Morrisville, NC 27560 Phone: 919 862-1000 Fax: 919 862-1095 Web: www.salix.com Email: investor.relations@salix.com

Industry	MED-DRUGS
Sector:	Medical

Fiscal Year End	December
Last Reported Quarter	09/30/09
Next EPS Date	03/09/2010

Price and Volume Information

Zacks Rank
Yesterday's Close	23.56
52 Week High	24.29
52 Week Low	6.14
Beta	0.79
20 Day Moving Average	901,579.69
Target Price Consensus	27.06

% Price Change
4 Week	18.33
12 Week	94.23
YTD	166.82

% Price Change Relative to S&P 500
4 Week	13.81
12 Week	75.32
YTD	119.42

Share Information
Shares Outstanding (millions)	48.82
Market Capitalization (millions)	1,150.29
Short Ratio	5.31
Last Split Date	07/13/2004

Dividend Information
Dividend Yield	0.00%
Annual Dividend	$0.00
Payout Ratio	0.00
Change in Payout Ratio	0.00
Last Dividend Payout / Amount	NA / $0.00

EPS Information
Current Quarter EPS Consensus Estimate	-0.14
Current Year EPS Consensus Estimate	-0.90
Estimated Long-Term EPS Growth Rate	43.50
Next EPS Report Date	03/09/2010

Consensus Recommendations
Current (1=Strong Buy, 5=Strong Sell)	1.75
30 Days Ago	2.11
60 Days Ago	2.25
90 Days Ago	2.75

Fundamental Ratios

P/E
Current FY Estimate:	-
Trailing 12 Months:	-
PEG Ratio	-

EPS Growth
vs. Previous Year	-36.36%
vs. Previous Quarter	53.12%

Sales Growth
vs. Previous Year	53.15%
vs. Previous Quarter:	25.70%

Price Ratios
Price/Book	4.48
Price/Cash Flow	-
Price / Sales	5.15

ROE
09/30/09	-18.70
06/30/09	-17.77
03/31/09	-14.41

ROA
09/30/09	-12.04
06/30/09	-11.27
03/31/09	-9.51

Current Ratio
09/30/09	-
06/30/09	-
03/31/09	2.60

Quick Ratio
09/30/09	-
06/30/09	-
03/31/09	2.26

Operating Margin
09/30/09	-21.11
06/30/09	-22.57
03/31/09	-19.55

Net Margin
09/30/09	-
06/30/09	-
03/31/09	-19.96

Pre-Tax Margin
09/30/09	-
06/30/09	-
03/31/09	-19.96

Book Value
09/30/09	-
06/30/09	-
03/31/09	5.26

Inventory Turnover
09/30/09	-
06/30/09	-
03/31/09	1.82

Debt-to-Equity
09/30/09	-
06/30/09	-
03/31/09	0.25

Debt to Capital
09/30/09	-
06/30/09	-
03/31/09	19.96


About Zacks \| Advertise \| Media \| Careers \| Contact Us \| Help Disclaimer \| Privacy Policy \| Sitemap NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed. Copyright 2009 Zacks Investment Research